Stem Cell Therapeutics Corp. Announces Dr. Alan Moore's Presentation at the BioFinance 2010 Meeting April 6-8, 2010, Toronto, Ca
April 06 2010 - 7:00AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT") today
announced that Dr. Alan Moore, President CEO of SCT, will be
presenting on behalf of SCT at the BioFinance 2010 meeting which is
being held in Toronto, Canada, April 6-8, 2010.
Dr. Alan Moore will be speaking at 9:30 a.m., on April 7th,
2010, in the Simcoe Room of the Toronto Marriott Eaton Centre. Dr.
Moore's presentation will discuss the progress that SCT has made in
2009 and the future direction that company will pursue in 2010 with
its product line.
Dr. Alan Moore, President and CEO of SCT, commented as
follows:
"We are excited to have this opportunity to communicate with the
BioFinance community on our Company's achievements and the future
potential of SCT as we continue our product development.
Our outlook for this year includes:
- Completion of Phase IIb stroke trial patient analysis and announcement
of top-line results;
- The opportunity to build on our strengths with the initiation of
additional clinical programs in Traumatic Brain Injury and Multiple
Sclerosis."
About the BioFinance 2010 meeting (http://www.biofinance.ca/):
BioFinance 2010 is the leading investor conference in Canada for
the life sciences industry. This three-day event brings together
key industry players interested in investment opportunities and
issues affecting companies in the life sciences sector. Presenting
companies will span a range of industries including: biologics,
medical devices, drug delivery, vaccines, diagnostics, bio-energy,
green technologies, bio materials, industrial biotech, and research
services.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available. Except for historical information, this press release
may contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO 403-245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager
403-245-5495 ext. 221 adasilva@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024